Market Place
Sourcing Support
Corsera launches with $50M for predictive AI tool, RNAi Asset
02 Sep 2025 //
FIERCE BIOTECH
HELIOS-B Phase 3 Study Presented at ESC Congress 2025
31 Aug 2025 //
BUSINESSWIRE
Roche, Alnylam to Initiate Phase 3 Trial of Zilebesiran
31 Aug 2025 //
PRESS RELEASE
Alnylam to Webcast at September Investor Conferences
27 Aug 2025 //
BUSINESSWIRE
Scenic Enters License and Research Agreement with Alnylam
26 Aug 2025 //
GLOBENEWSWIRE
Alnylam Showcases RNAi Therapeutics for Cardiovascular Disease
11 Aug 2025 //
BUSINESSWIRE
Alnylam`s Webcast at Canaccord Genuity 45th Growth Conference
05 Aug 2025 //
BUSINESSWIRE
Alnylam`s Market Cap Jumps Past $50 B
01 Aug 2025 //
FIERCE PHARMA
Alnylam Pharma Q2 2025 Financial Results and Recent Progress
31 Jul 2025 //
BUSINESSWIRE
Alnylam to Webcast Q2 2025 Financial Results Call
17 Jul 2025 //
BUSINESSWIRE
Alnylam Promotes Pushkal Garg to R&D Chief Role
18 Jun 2025 //
BUSINESSWIRE
Alnylam Receives European Commission Approval for Amvuttra
10 Jun 2025 //
BIOSAPCE
Alnylam to Webcast at Goldman Sachs Healthcare Conference
28 May 2025 //
BUSINESSWIRE
Alnylam Issues 2024 Corporate Responsibility Report
20 May 2025 //
BUSINESSWIRE
AMVUTTRA® (vutrisiran) Reduces Mortality and Cardiovascular Event
17 May 2025 //
BUSINESSWIRE
Alnylam drops Covid vaccine patent case against Pfizer, BioNTech
14 May 2025 //
REUTERS
Alnylam to Present HELIOS-B Data at Heart Meeting
12 May 2025 //
BUSINESSWIRE
Alnylam to Webcast at BofA Securities 2025 Health Care Conference
05 May 2025 //
BUSINESSWIRE
Alnylam Pharmaceuticals Reports Q1 2025 Financial Results
01 May 2025 //
BUSINESSWIRE
Alnylam Gets CHMP Backing for Vutrisiran in ATTR-CM
28 Apr 2025 //
BUSINESSWIRE
Alnylam to Discuss Q1 2025 Financial Results in Webcast
17 Apr 2025 //
BUSINESSWIRE
Alnylam to Webcast at Needham 24th Annual Healthcare Conference
01 Apr 2025 //
BUSINESSWIRE
Alnylam presents Phase 3 on Vutrisiran in ATTR-CM at ACC 2025
31 Mar 2025 //
BUSINESSWIRE
FDA Approves Amvuttra (Vutrisiran) for ATTR-CM
21 Mar 2025 //
BUSINESSWIRE
Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum
11 Mar 2025 //
BUSINESSWIRE
Alnylam Announces Retirement Of Co-Founder Dr. Phillip A. Sharp
05 Mar 2025 //
BUSINESSWIRE
Alnylam Showcase Pipeline Advances & Platform Innovation At R&D Day
25 Feb 2025 //
BUSINESSWIRE
Market growth will help spark sales of Amvuttra, Alnylam says
13 Feb 2025 //
FIERCE PHARMA
Alnylam Pharma Reports Q4 & Full Year 2024 Financial Results
13 Feb 2025 //
BUSINESSWIRE
Alnylam to Conference Call FOR Q4 & 2024 Financial Results
30 Jan 2025 //
BUSINESSWIRE
Alnylam Announces 2024 Revenues & 2025 Guidance With Pipeline Goals
12 Jan 2025 //
BUSINESSWIRE
Alnylam to Webcast Presentation at 43rd J.P. Morgan Conference
06 Jan 2025 //
BUSINESSWIRE
Alnylam to Webcast Presentation at Piper Sandler 36th Conference
27 Nov 2024 //
BUSINESSWIRE
Alnylam Announces Nucresiran Phase 1 Data on TTR Knockdown
17 Nov 2024 //
BUSINESSWIRE
Alnylam abandons clinical-stage Type 2 diabetes asset
31 Oct 2024 //
FIERCE BIOTECH
Alnylam to Present TTR Data & Hypertension Program at AHA 2024
30 Oct 2024 //
BUSINESSWIRE
Alnylam to Webcast Conference Discussing Q3 2024 Financial Results
17 Oct 2024 //
BUSINESSWIRE
Alnylam Submits Application For Vutrisiran In ATTR Amyloidosis
16 Oct 2024 //
BUSINESSWIRE
Alnylam Submits sNDA to FDA For Vutrisiran In ATTR-CM
09 Oct 2024 //
BUSINESSWIRE
Alnylam drops patent lawsuit against Moderna over Covid-19 vaccine
07 Oct 2024 //
ENDPTS
Alnylam: New Data From HELIOS-B Study At Heart Failure Meeting
29 Sep 2024 //
BUSINESSWIRE
Alnylam to Webcast TTR Investor Day
26 Sep 2024 //
BUSINESSWIRE
Alnylam shares slide after heart drug data fails to impress investors
30 Aug 2024 //
REUTERS
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
28 Aug 2024 //
BUSINESSWIRE
Alnylam To Present HELIOS-B Phase 3 Results At ESC Congress 2024
07 Aug 2024 //
BUSINESSWIRE
Alnylam Reports Q2 2024 Results And Recent Highlights
01 Aug 2024 //
BUSINESSWIRE
Alnylam To Webcast Q2 2024 Financial Results Conference Call
18 Jul 2024 //
BUSINESSWIRE
Alnylam touts `big-win scenario` for closely watched heart trial
25 Jun 2024 //
FIERCE PHARMA
Alnylam Issues 2023 Corporate Responsibility Report
07 May 2024 //
BUSINESSWIRE
Alnylam Reports Q1 2024 Results, Highlights Recent Activity
02 May 2024 //
BUSINESSWIRE
Medison, Alnylam Expand RNAi Deal To More Regions
30 Apr 2024 //
PR NEWSWIRE
Medison, Alnylam Expand RNAi Partnership To More Regions
30 Apr 2024 //
PR NEWSWIRE
Experts paint tough path ahead of Alnylam`s key ATTR-CM readout
22 Apr 2024 //
FIERCE PHARMA
Chugai in-licenses RNAi therapeutic zilebesiran for hyp.high cardiovascular risk
20 Apr 2024 //
PHARMABIZ
Alnylam To Webcast Q1 2024 Financial Results Call
18 Apr 2024 //
BUSINESSWIRE
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran
07 Apr 2024 //
BUSINESSWIRE
Alnylam to Webcast to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran
20 Mar 2024 //
BUSINESSWIRE
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign
13 Mar 2024 //
BUSINESSWIRE
Alnylam takes a family road trip to talk about health history
13 Mar 2024 //
ENDPTS
Roche, Alnylam say blood pressure drug succeeds in mid-stage trial
06 Mar 2024 //
BIOPHARMA DIVE
